During the past decade several display methods and other library screening techniques
have been developed for isolating monoclonal antibodies (mAbs) from large collections of …

The advent in recent years of the application of tetrameric arrays of class I peptide–MHC
complexes now enables us to detect and study rare populations of antigen‐specific CD8+ T …

The advent in recent years of the application of tetrameric arrays of class I peptide-MHC
complexes now enables us to detect and study rare populations of Ag-specific CD8+ T cells …

Tumor-associated, MHC-restricted peptides, recognized by tumor-specific CD8+
lymphocytes, are desirable targets for novel approaches in immunotherapy because of their …

Phage display (Smith, 1985) was the first molecular diversity selection platform and the
conceptual forerunner of all subsequent molecular diversity techniques. An analysis of the …

The generation of new drugs has long involved the screening of hundreds of thousands of
components with well defined in vitro tests, seeking compounds to mimic as closely as …

The brain is a specialized immune site representing a unique tumor microenvironment. The
availability of fresh brain tumor material for ex vivo analysis is often limited because large …

The Wilms tumor 1 (WT1) oncoprotein is an intracellular, oncogenic transcription factor that
is overexpressed in a wide range of leukemias and solid cancers. RMFPNAPYL (RMF), a …

Monoclonal antibodies are among the most clinically effective drugs used to treat cancer.
However, their target repertoire is limited as there are relatively few tumor-specific or tumor …

Cancer immunotherapy has been regarded as the most significant scientific breakthrough of
2013, and antibody therapy is at the core of this breakthrough. Despite significant success …